Acacia Pharma is preparing for filing an NDA for BAREMSIS™ for the treatments of post operative nausea & vomiting.
Atox Bio is a late stage biotechnology company that develops novel immunomodulators to treat critically ill patients. Initial focus is on patients with Necrotizing Soft Tissue Infections (“flesh eating bacteria”), a rare, life threatening, infection for which no current therapy exists. AB103, the company’s lead product, is studied in ACCUTE (AB103 Clinical Composite endpoint StUdy in necrotizing soft Tissue InfEctions), a phase 3 clinical trial. AB103 received Orphan Drug designation from the FDA and EMA and Fast Track designation from the FDA.
Biom’Up is a specialist in collagen-based absorbable medical devices for biosurgery and is developing a new generation hemostatic product, HEMOBLAST TM. HEMOBLASTTM Bellows is currently being tested in a prospective, randomized, controlled, multicenter, pivotal, clinical investigation evaluating the safety and efficacy in Cardiothoracic, Abdominal, and Orthopedic Lower Extremity Surgeries.
BONESUPPORT has a platform for delivering drugs to bone using CERAMENT™. This carrier is an injectable radio opaque bone void filler that rapidly remodels into bone. Bonesupport markets and sells CERAMENT™ in EU and USA and CERAMENT™ loaded with the antibiotics Gentamicin or Vancomycin in EU.
Cydan Development is an orphan drug accelerator that identifies and de-risks drug candidates targeting orphan and rare diseases and form stand-alone companies and strategic partnerships around successful such candidates.
DySIS develops and markets next generation colposcopes for early detection and diagnosis of cervical cancer. The DySIS colposcope is a high resolution digital colposcope with an adjunctive map. The DySISmap is generated by a proprietary technology that measures the aceto-whitening reaction and summarizes it in the form of an intuitive map. The DySISmap is overlaid on the live image of the cervix to help with the identification of the most relevant biopsy sites.
Enterome is pioneering the development of novel drugs and diagnostics to support a personalized therapeutic approach of microbiome-related diseases with a special focus on Inflammatory Bowel Disease.
Iconic Therapeutics is a clinical stage company dedicated to the role of Tissue Factor (TF) in retinal disease and cancer. The company’s lead product candidate, ICON-1, is a novel human fusion protein that addresses the root causes of acute vision loss in AMD, and is currently in Phase II.
Imara is developing a novel oral treatment for patients with sickle cell disease and other haemoglobinopathies.
PsiOxus is developing novel therapeutics based on our platform of tumour-targeted delivery with the oncolytic vaccine, enadenotucirev. Enadenotucirev can be administered systemically, and replicates in and kill cancer cells, but not normal cells.
Sanifit is a biopharmaceutical company focused on the development of SNF472 – an experimental drug for the treatment of cardiovascular diseases linked to calcification in the End Stage Renal Disease (ESRD) population undergoing haemodialysis. The company has completed phase Ia studies in healthy volunteers and a phase Ib/IIa study in haemodialysis patients. Sanifit plans to start a phase IIb study in ESRD and to extend the orphan program in calciphylaxis into phase II/III clinical trials.
scPharmaceuticals’ proprietary device technology enables subcutaneous administration of parenteral drugs. The sc2Wear™ pump, serves as the platform for a pipeline of proven drugs that enables a new anytime-anywhere treatment model that is independent of a clinical setting. It is a convenient, comfortable, full-featured patch pump device that facilitates subcutaneous drug administration over durations, rates and volumes that can be tailored to specific drugs.
Spero is a biopharmaceutical company developing a pipeline of novel treatments for bacterial infections. The company is pioneering an entirely new therapeutic platform called the Potentiator; this approach has yielded multiple molecules that enhance the utility and potency of many classes of existing drugs to include Gram-negative pathogens. Spero’s DHFR program is exploring the expansion of a novel antifolate’s antibacterial spectrum to treat trimethoprim resistance isolates including Gram-negative pathogens.
Thesan Pharmaceuticals is a biopharmaceutical company based in San Diego, US, dedicated to the development of novel therapeutics for disorders of the skin.
Veloxis is a specialty pharmaceutical company committed to improving the lives of transplant patients. It’s unique, patented delivery technology, MeltDose®, is designed to enhance the absorption and bioavailability of select orally administered drugs. Veloxis is commercializing Envarsus directly in the USA and through it’s partner Chiesi in Europe.
VHsquared is a clinical stage company focused on transformational oral biologics – Vorabodies™ – for inflammatory bowel disease. Vorabodies™ are oral gut-restricted domain antibodies targeting local immuno-inflammatory targets in the GI tract.